HagaZiekenhuis   Report issue

Academic/Hospital Phase 2 Phase 3
Founded: Hague Netherlands (2004)

Organization Overview

First Clinical Trial
2004
NCT00043134
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

HagaZiekenhuis | Hagaziekenhuis, Den Haag | HAGA Ziekenhuis (HagaZiekenhuis van Den Haag) | HagaZiekenhuis - Locatie Leyenburg | HagaZiekenhuis, the Hague, The Netherlands | HagaZiekenhuis, The Hague, The Netherlands

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Arthritis (Phase 2)

Arthritis, Psoriatic (Phase 2)

Carcinoma, Non-Small-Cell Lung (Phase 2)

Fistula (Phase 2)

Leukemia (Phase 3)

Leukemia, Myeloid, Acute (Phase 3)

Myelodysplastic-Myeloproliferative Diseases (Phase 3)

Myelodysplastic Syndromes (Phase 3)

Myeloproliferative Disorders (Phase 3)

Neointima (Phase 2)

Preleukemia (Phase 3)

Syndrome (Phase 3)

Vascular Remodeling (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 7
  • # of Trial APIs: 12